Objective: To analyze trends in screening and invasive prenatal diagnosis of chromosome abnormalities (CA) over a 13-year period and correlate them to changes in the national prenatal screening policy. Methods: We retrospectively reviewed Down syndrome (DS) screening tests and fetal karyotypes obtained by prenatal invasive testing (IT) in our fetal medicine unit between January 1999 and December 2011. Results: A total of 24,226 prenatal screening tests for DS and 11,045 invasive procedures have been analyzed. Over a 13-year period, utilization of non-invasive screening methods has significantly increased from 57% to 89%. The percentage of invasive procedures has declined from 49% to 12%, although the percentage of IT performed for maternal anxiety has increased from 22% to 55%. The percentage of detected CA increased from 2.5% to 5.9%. Overall, 31 invasive procedures are needed to diagnose 1 abnormal case, being 23 procedures in medical indications and 241 procedures in non-medical indications. Conclusions: Our experience on screening and invasive prenatal diagnostic practice shows a decrease of the number of IT, with a parallel decline in medical indications. There is an increasing efficiency of prenatal screening program to detect CA. Despite the increasing screening policies, our population shows a growing request for prenatal IT. The a priori low risk population shows a not negligible residual risk for relevant CA. This observation challenges the current prenatal screening strategy focused on DS; showing that the residual risk is higher than the current cut-off used to indicate an invasive technique.
References
[1]
Sherman, L.; Allen, E.G.; Bean, L.H.; Freeman, S.B. Epidemiology of Down syndrome. Ment Retard Dev. Disabil. Res. Rev. 2007, 13, 221–227, doi:10.1002/mrdd.20157.
[2]
Ogivile, C.M. Prenatal diagnosis for chromosome abnormalities: past, present and future. Pathol. Biol. 2003, 51, 156–160, doi:10.1016/S0369-8114(03)00017-8.
[3]
Lewis, M.; Faed, M.J.; Howie, P.W. Screening for Down’s syndrome based on individual risk. BMJ 1991, 7, 551–553.
[4]
Spencer, K.; Spencer, C.E.; Power, M.; Dawson, C.; Nicolaides, K.H. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: A review of three years prospective experience. BJOG 2003, 110, 281–286, doi:10.1046/j.1471-0528.2003.02246.x.
[5]
Borrell, A.; Casals, E.; Fortuny, A.; Farre, M.T.; Gonce, A.; Sanchez, A.; Soler, A.; Cararach, V.; Vanrell, J.A. First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional study. Prenatal Diag. 2004, 24, 541–545, doi:10.1002/pd.949.
[6]
Comas Gabriel, C.; Echevarria Tellería, M.; Mu？oz Prades, A.; Rodríguez García, I.; Carrera Martínez, M.; Serra Zantop, B. Invasive prenatal diagnostic practice: A review of a ten years experience at Dexeus Institut. Prenatal Diag. 2011, 22, 117–127, doi:10.1016/j.diapre.2011.07.002.
[7]
Ekelund, C.K.; J？rgensen, F.S.; Petersen, O.B.; Sundberg, K.; Tabor, A. Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study. BMJ 2008, 27.
[8]
Vestergaard, C.H.; Lidegaard, ？.; Tabor, A. Invasive prenatal diagnostic practice in Denmark 1996 to 2006. Acta Obstet. Gynecol. Scand. 2009, 88, 362–365, doi:10.1080/00016340902730367.
[9]
Lichtenbelt, K.D.; Alizadeh, B.Z.; Scheffer, P.G.; Stoutenbeek, P.; Schielen, P.C.; Page-Christiaens, L.C.; Schuring-Blom, G.H. Trends in the utilization of invasive prenatal diagnosis in The Netherlands during 2000–2009. Prenatal Diag. 2011, 31, 765–772, doi:10.1002/pd.2764.
[10]
Morris, J.K.; Waters, J.J.; de Souza, E. The population impact of screening for Down syndrome: Audit of 19326 invasive diagnostic tests in England and Wales in 2008. Prenatal Diag. 2012, 32, 596–601, doi:10.1002/pd.3866.
[11]
Mademont-Soler, I.; Morales, C.; Clusellas, N.; Soler, A.; Sánchez, A. Prenatal cytogenetic diagnosis in Spain: Analysis and evaluation of the results obtained from amniotic fluid samples during the last decade. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 157, 156–160, doi:10.1016/j.ejogrb.2011.03.016.
[12]
Han, S.H.; An, J.W.; Jeong, G.Y.; Yoon, H.R.; Lee, A.; Yang, Y.H.; Lee, K.P.; Lee, K.R. Clinical and cytogenetic findings on 31,615 mid-trimester amniocenteses. Korean J. Lab. Med. 2008, 28, 378–385, doi:10.3343/kjlm.2008.28.5.378.
[13]
Hassold, T.; Abruzzo, M.; Adkins, K.; Griffin, D.; Merrill, M.; Millie, E.; Saker, D.; Shen, J.; Zaragoza, M. Human aneuploidy: incidence, origin, and etiology. Environ. Mol. Mutagen. 1996, 28, 167–175, doi:10.1002/(SICI)1098-2280(1996)28:3<167::AID-EM2>3.0.CO;2-B.
[14]
Verp, M.S.; Bombard, A.T.; Simpson, J.L.; Elias, S. Parental decision following prenatal diagnosis of fetal chromosome abnormality. Am. J. Med. Genet. 1988, 29, 613–622, doi:10.1002/ajmg.1320290320.
[15]
Ratcliffe, S. Long-term outcome in children of sex chromosome abnormalities. Arch. Dis. Child. 1999, 80, 192–195, doi:10.1136/adc.80.2.192.
[16]
Linden, M.G.; Bender, B.G. Fifty-one prenatally diagnosed children and adolescents with sex chromosome abnormalities. Am. J. Med. Genet. 2002, 110, 11–18, doi:10.1002/ajmg.10394.
[17]
Christian, S.M.; Koehn, D.; Pillay, R.; MacDougall, A.; Wilson, R.D. Parental decisions following prenatal diagnosis of sex chromosome aneuploidy: A trend over time. Prenatal Diag. 2000, 20, 37–40, doi:10.1002/(SICI)1097-0223(200001)20:1<37::AID-PD748>3.0.CO;2-G.
[18]
Hamamy, H.A.; Dahoun, S. Parental decisions following the prenatal diagnosis of sex chromosome abnormalities. Eur. J. Obstet. Gynecol. Reprod. Biol. 2004, 116, 58–62, doi:10.1016/j.ejogrb.2003.12.029.
[19]
Shaffer, B.L.; Caughey, A.B.; Norton, M.E. Variation in the decision to terminate pregnancy in the setting of fetal aneuploidy. Prenatal Diag. 2006, 26, 667–671, doi:10.1002/pd.1462.
[20]
Lee, C.N.; Lin, S.Y.; Lin, C.H.; Shih, J.C.; Lin, T.H.; Su, Y.N. Clinical utility of array comparative genomic hybridisation for prenatal diagnosis: A cohort study of 3171 pregnancies. BJOG 2012, 119, 1282, doi:10.1111/j.1471-0528.2012.03419.x.
[21]
Querejeta, M.E.; Nieva, B.; Navajas, J.; Cigudosa, J.C.; Suela, J. Diagnóstico prenatal y array-CGH II: gestaciones de bajo riesgo. Prenatal Diag. 2012, 23, 49–55, doi:10.1016/j.diapre.2012.01.004.
Fiorentino, F.; Caiazzo, F.; Napolitano, S.; Spizzichino, L.; Bono, S.; Sessa, M.T.; Nuccitelli, A.; Biricik, A.; Gordon, A.; Rizzo, G; Baldi, M. Introducing array comparative genomic hybridization into routine prenatal diagnosis practice: A prospective study on over 1000 consecutive clinical cases. Prenatal Diag. 2011, 31, 1270–1282, doi:10.1002/pd.2884.
[24]
Breman, A.; Pursley, A.N.; Hixson, P.; Bi, W.; Ward, P.; Bacino, C.A.; Shaw, C.H.; Lupski, J.R.; Beaudet, A.; Patel, A.; Cheung, S.W.; van den Veyver, I. Prenatal chromosomal microarray analysis in a diagnostic laboratory; experience with >1000 cases and review of the literature. Prenatal Diag. 2012, 32, 351–361, doi:10.1002/pd.3861.
[25]
Fiorentino, F.; Baldi, M. Re: Microarray application in prenatal diagnosis: A position statement from cytogenetics working group of the Italian Society of Human Genetics (SIGU), Novemebr 2011. Ultrasound Obstet. Gynecol. 2012, 39, 601–602, doi:10.1002/uog.11158.
[26]
Hillman, S.C.; Pretlove, S.; Coomarasamy, A.; McMullan, D.J.; Davison, E.V.; Maher, E.R.; Kilby, M.D. Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: A systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2011, 37, 6–14, doi:10.1002/uog.7754.
[27]
Novelli, A.; Grati, F.R.; Ballarati, L.; Bernardini, L.; Bizzoco, D.; Camurri, L.; Casalone, R.; Cardarelli, L.; Cavalli, P.; Ciccone, R.; et al. Microarray application in prenatal diagnosis: A position statement from the cytogenetics working group of the Italian Society of Human Genetics (SIGU), November 2011. Ultrasound Obstet. Gynecol. 2012, 39, 384–388, doi:10.1002/uog.11092.
[28]
Chiu, R.W.K.; Akolekar, R.; Zheng, Y.W.L.; Leung, T.K.; Sun, H.; Chan, K.C.A.; Lun, F.M.F.; Go, A.T.J.I.; Lau, E.T.; To, W.W.K. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: Large scale validation study. Brit. Med. J. 2011, 342, c7401.
[29]
Sparks, A.B.; Struble, C.A.; Wang, E.T.; Song, K.; Oliphant, A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: Evaluation for trisomy 21 and trisomy 18. Am. J. Obstet. Gynecol. 2012, 206, 319e1–319e9.
[30]
Norton, M.E.; Brar, H.; Weiss, J.; Karimi, A.; Laurent, L.C.; Caughey, A.B.; Rodriguez, M.H.; Williams, J.; Mitchell, M.E.; Adair, C.D.; et al. Non-Invasive Chromosomal Evaluation (NICE) Study: Results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am. J. Obstet. Gynecol. 2012, 207, 137e1–137e8.
